LRRK2 Degrading Compounds for Parkinson's Disease Treatment

The USPTO has published a new patent application (US20260085066A1) detailing bifunctional compounds designed to degrade LRRK2, a protein implicated in Parkinson's Disease. The application covers pharmaceutical compositions and methods for treating LRRK2-associated disorders.

Patent for SGLT Inhibitor Synthesis Intermediate

The USPTO has published a patent application for a crystalline form of an intermediate useful in the synthesis of SGLT inhibitors. The application details a method to improve purification efficiency and minimize related substances in the final product, potentially increasing yield.

Patent Application: Benzofuranyl/Benzoxazolyl Compounds for Cancer Treatment

The USPTO has published a patent application (US20260085064A1) for substituted benzofuranyl and benzoxazolyl compounds, including their synthesis and use in treating cancer. The application was filed on May 2, 2025, by inventors from institutions including the University of Texas MD Anderson Cancer Center.

Patent Application: Benzamide Compounds for SARS-CoV-2 PLpro Inhibition

The USPTO has published a new patent application (US20260085063A1) detailing benzamide compounds and methods for inhibiting SARS-CoV-2 PLpro. The application was filed on August 19, 2025, by inventors Jun Wang, Bin Tan, and Prakash Daulat Jadhav.

Novel compounds as CK2 inhibitors for disease treatment

The USPTO has published a patent application (US20260085062A1) for novel compounds identified as CK2 inhibitors. These compounds are intended for the treatment and prevention of various diseases, including cancer, viral infections, and neurodegenerative disorders. The application details specific chemical structures and their potential pharmaceutical uses.

Patent Application: Phthalazine Derivatives as Pyruvate Kinase Modulators

The USPTO has published a new patent application (US20260085061A1) for phthalazine derivatives as pyruvate kinase modulators, assigned to Sitryx Therapeutics Limited. The application was filed on September 25, 2025.

Patent Application: Therapeutic Compounds - Orexin-1 Receptor Antagonists

The USPTO has published a new patent application (US20260085060A1) for therapeutic compounds that act as orexin-1 receptor antagonists. The application, filed on September 25, 2025, details compounds with structural formula (I), their preparation, and pharmaceutical uses.

System for updating medical facility uses AI

The USPTO has published a patent application for a system that uses AI to determine whether to update a medical facility. The system retrieves information from the facility, applies an AI model, and initiates maintenance or upgrades based on the determination. The application was filed on September 4, 2023.

Patent Application US20260085058A1 for SOS1 Degraders Treating Cancers

The USPTO has published patent application US20260085058A1, which relates to compounds that degrade son of sevenless homolog 1 (SOS1) and their use in treating cancers, particularly KRAS-mutant cancers. The application was filed on August 11, 2023.

Substituted Indazoles for Treating Animal Allergic Inflammatory Diseases

The USPTO has published a patent application detailing the use of substituted indazoles for the treatment and prevention of allergic and inflammatory diseases in animals. The application, filed on October 9, 2025, outlines specific compounds and their potential applications in veterinary medicine.